Printer Friendly

Diagnostic Products Corporation Released from FDA's Application Integrity Policy.

LOS ANGELES -- Diagnostic Products Corporation (NYSE:DP) reported that they have received a letter from the U.S. Food and Drug Administration (FDA) lifting the Application Integrity Policy (AIP). The original restriction suspended the FDA's review of pending diagnostic test applications DPC submitted and deferred scientific review of any future submissions until the AIP issue was resolved.

"We are very happy to have this issue successfully resolved," stated Michael Ziering, CEO of Diagnostic Products Corporation.

About Diagnostic Products Corporation

Diagnostic Products Corporation, founded in 1971, is the global leader dedicated exclusively to immunodiagnostics. DPC's product menu includes over 75 immunoassays and more than 360 specific allergens and allergy panels. In addition, DPC addresses the chemistry and laboratory automation testing needs of its customers through partnerships with manufacturers of chemistry systems and reagents. The combined chemistry and immunoassay menu is one of the largest and most diversified available, covering most laboratory tests requested. DPC also designs and manufactures automated laboratory instrumentation, which provides fast, accurate results while reducing labor and reagent costs. DPC sells its products to hospitals, clinics and laboratories in more than 100 countries. Additional Company information can be found on DPC's website at www.dpcweb.com.

Except for the historical information contained herein, this press release contains forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially. These factors include the effects of governmental or other actions relating to the FDA's decision that its Application Integrity Policy should be applied to the Company or relating to the Company's Chinese affiliate; the rate of customer demand for the Company's products; the Company's ability to successfully market new and existing products; its dependence on certain suppliers; domestic and foreign government regulation; its ability to keep abreast of technological innovations and to translate them into new products; competition; political and economic instability in certain markets including the movements of foreign currencies relative to the dollar; and other risks and uncertainties disclosed from time to time in the Company's SEC reports and filings.
COPYRIGHT 2005 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2005, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Geographic Code:1USA
Date:Sep 7, 2005
Words:336
Previous Article:Insider Pages Gives Away Free Gas for Reviews of Local Businesses; Local Search Engine Hits Quarter of a Million Customer Reviews and Drives for More.
Next Article:State of Michigan Selects zNose for Homeland Security Application.
Topics:


Related Articles
Blood supply scrutinized: FDA report cites more than 200 violations.
Diagnostic Products Corporation Announces Annual Meeting Date.
Diagnostic Products Corporation's RealTime Solutions Product Wins Gold M2M Magazine's Value Chain Award.
DPC's Immunoassay Workcell Now Available.
Diagnostic Products Corporation Schedules Conference Call to Discuss Second Quarter 2005 Results.
Frost & Sullivan Accolade for Diagnostic Products Corporation's Customer Service Innovation.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters